Company Overview
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Why Investors Should Care
Revenue has grown at a 11.9% CAGR over the past five years.
Maintains a net profit margin of 57.6%.
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Dec 2025 Revenue of $51.66M (+12.4% YoY); net profit $-34.28M.
- Trailing 12 Months Year-on-year growth — revenue +18.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.87% |
| 1 Year: | 18.40% |
Stock Price Performance
| 1 Year: | -52.43% |
| 6 Months: | +19.25% |
| 3 Months: | +13.04% |
| 1 Month: | -14.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.71 · Neutral
P/E of 30.35 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 57.6%.
- Compounding revenue at 11.9% over 5 years.
CONS
- Trading 53.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LNSR LENSAR, Inc. R2KPHARMA | 6.07 | 30.35 | $74.58M | 0.00% | -79.65% | - | 11.87% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 6.96M | 4.93M | 4.58M | 6.07M | 5.93M | 6.78M | 6.99M | 7.94M | 6.62M | 6.28M | 6.62M | 10.32M | 8.27M | 8.64M | 10.68M | 11.81M | 12.28M | 12.29M | 12.76M | 11.75M |
| Operating Income | - | - | -5.34M | -3.10M | -3.84M | -4.71M | -5.20M | -4.38M | -6.17M | -6.68M | -6.80M | -4.08M | -4.36M | -2.87M | -2.04M | -2.85M | -5.28M | -1.25M | -5.79M | -6.29M | -7.58M | 2.24M |
| Net Income | -2.58M | -3.79M | -5.82M | -3.69M | -4.50M | -4.76M | -5.18M | -4.36M | -6.16M | -6.67M | -6.76M | -3.99M | -4.27M | -8.75M | 2.57M | -2.16M | -9.04M | -1.50M | -27.34M | -1.76M | -3.71M | 36.33M |
| Diluted EPS | - | - | - | - | - | - | - | -0.47 | -0.65 | -0.67 | -0.67 | -0.39 | -0.40 | -0.81 | -0.23 | -0.19 | -0.79 | -0.13 | -2.32 | -0.15 | -0.31 | 0.00 |
| R&D Expense | - | - | 4.33M | 1.57M | 1.43M | 2.00M | 2.75M | 3.01M | 3.18M | 4.79M | 3.83M | 1.58M | 1.65M | 1.50M | 1.53M | 1.44M | 1.35M | 1.20M | 1.53M | 1.43M | 1.37M | 1.39M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 26.35M | 22.78M | 29.49M | 29.44M | 35.72M | 45.96M | 51.66M |
| Operating Income | -12.71M | -18.50M | -19.65M | -20.18M | -12.23M | -10.66M | -24.58M |
| Net Income | -14.66M | -19.77M | -19.60M | -19.91M | -14.38M | -31.40M | -34.28M |
| Diluted EPS | - | - | -2.09 | -1.96 | -1.31 | -2.73 | -2.87 |
| R&D Expense | 7.57M | 7.55M | 12.36M | 11.81M | 6.14M | 5.33M | 5.62M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 34.54M | 79.12M | - | 55.84M | 69.58M | 66.30M | 71.43M |
| Current Assets | - | - | - | - | 33.72M | 46.44M | 41.98M | 46.77M |
| Cash & Equivalents | - | 4.62M | 40.60M | - | 14.67M | 20.62M | 16.26M | 12.97M |
| Inventory | - | - | - | - | 11.74M | 15.69M | 11.43M | 21.52M |
| Receivables | - | - | - | - | 6.04M | 4.00M | 6.08M | 6.38M |
| Total Liabilities | - | 65.09M | 11.91M | - | 13.86M | 36.16M | 61.44M | 97.45M |
| Current Liabilities | - | 7.83M | 8.47M | - | 11.42M | 11.63M | 15.00M | 40.57M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 2.80M | 2.31M | 2.61M | 2.73M |
| Total Equity | -20.46M | -30.55M | 67.21M | - | 41.98M | 33.43M | 4.86M | -26.02M |
| Shares Outstanding | - | - | - | - | 11.09M | 11.33M | 11.65M | 11.99M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.59M | -13.79M | -8.97M | -14.86M | -9.66M | -2.27M | -14.83M |
| Investing Cash Flow | -2.09M | -326.00K | -354.00K | -115.00K | -4.16M | -2.16M | 1.28M |
| Financing Cash Flow | 15.95M | 50.00M | 361.00K | -1.99M | 19.76M | 78.00K | 10.26M |
| Capital Expenditure | -389.00K | -366.00K | -354.00K | -115.00K | -236.00K | -156.00K | -83.00K |
| Free Cash Flow | -12.98M | -14.16M | -9.32M | -14.97M | -9.89M | -2.43M | -14.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -48.3% | -81.2% | -66.6% | -68.5% | -34.2% | -23.2% | -47.6% |
| Net Margin % | -55.6% | -86.8% | -66.5% | -67.6% | -40.3% | -68.3% | -66.4% |
| ROE % | 48.0% | -29.4% | - | -47.4% | -43.0% | -645.9% | 131.7% |
| ROCE % | -47.6% | -26.2% | - | -45.4% | -21.1% | -20.8% | -79.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Brandes Investment Partners L.P. | 8.75% | 1.08M | $6.85M |
| 2 | Vanguard Capital Management LLC | 3.28% | 402.81K | $2.57M |
| 3 | Groupe La Francaise | 1.74% | 213.54K | $1.36M |
| 4 | RBF Capital, LLC | 1.54% | 188.66K | $1.20M |
| 5 | Blackrock Inc. | 1.51% | 185.03K | $1.18M |
| 6 | CSS LLC | 1.33% | 163.45K | $1.04M |
| 7 | Dimensional Fund Advisors LP | 1.23% | 151.61K | $965.75K |
| 8 | Credit Industriel Et Commercial | 1.18% | 144.36K | $919.57K |
| 9 | Kerrisdale Advisers, Llc | 1.13% | 139.39K | $887.91K |
| 10 | Millennium Management Llc | 0.98% | 120.68K | $768.73K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LNSR
LNSR Nov 2026 10.000 call (LNSR261120C00010000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5neVJtWklYa3FDU2xLdnNLY3FTSkhTZmFfMTRsaEQ4V2pFNDVkSGQ3aGgwR3lnLTY1NXg2aUtjSUJFQlRva28tZGg3VEtvZTZaVDNhejczSFI5Y1RVc1luLUZFOG5aUQ?oc=5" target="_blank">LNSR Nov 2026 10.000 call (LN…
LNSR Nov 2026 10.000 call (LNSR261120C00010000) Interactive Stock Chart - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE05YWdaSlZJcEZuc3VRYjl5MTBydzhjZmw0SU1LMUVWZU5adFJGWnpxNXlVX0lLMHJNSjNFYXh0S2xXYXE4R0E2T1VqUFEybUFYdjZZdkROUTlVa0pSc0l2N0pPdEt3cTN3aHhhWkhR?oc=5" target="_blank">LNSR Nov 2026 10.00…
LENSAR (LNSR) Stock Profitability Breakthrough Faces Questions Over Margin Durability - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNczJfMEhHMmdHd2xXNm9HdjRYYkZaLTlPeWFjSkVrSkZWRHZoeHdMZmtxUnJEaGlFWUxYeHBUQW1RblB3NWlieTdGZXJ4WGNxOHU3SjU5NDRfTzdCczlLS3hQbFhnWWVhS2ZJUVhFQkRXVm1wZlYxbXVpMnRmanZEM2IwZHN0LXlGeUlHel…
Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOaHJjTkVQYzFrTElQMG9fbDl0R1c4V1h1dDg1NVd1eDhVdk42WWM4WXN4S18tV2V0VWRCUXBha3Mxd0FtY2thbmpMMDZnRDFNaFpUbGI0YmtnSjVUNDJ3Z1NoRmY3TzN2ZnhqYV85dEFxYS1nbU5fSV9tS2VySnZ3M1FiQkFGY0tqZV9XQW…
LNSR Nov 2026 10.000 call (LNSR261120C00010000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5jUEdZSTNnUE9SelpET0Y4ZXdTaElOeWNZcmRnN01MeFEwdmhZS3RHUm5nZHlXWVE3YWNsOFV1WEpIQm83Wm1GWGJiSWREWHZsb2VFNEd3RG9KejlpZ0hjMDVlcEpSZw?oc=5" target="_blank">LNSR Nov 2026 10.000 call (LN…
LNSR Nov 2026 10.000 call (LNSR261120C00010000) interactive stock chart - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBuVUlvX09hSWE0T1ljN3l3WWRQc3hRMjRlTm8tOHlpWW9Ya1ZPT0JnT0J6ekd6TGExRzg2dHJ1SnpoTW9XZHptRFQwdWhJYU1fOF9YN0F2UnBFWURVUXVZcVByOGZCMXlmSlNzRDF3?oc=5" target="_blank">LNSR Nov 2026 10.00…
LNSR — Frequently Asked Questions
What is the current share price of LENSAR, Inc. (LNSR)?
As of 2026-10-23 16:27 PDT, LENSAR, Inc. (LNSR) trades at $6.07 on NasdaqCM. Its 52-week range is $5.01 to $12.90.
What is the market capitalisation of LNSR?
LENSAR, Inc. (LNSR) has a market capitalisation of $74.58M on NasdaqCM.
What is the P/E ratio of LNSR?
LNSR trades at a trailing price-to-earnings (P/E) ratio of 30.35. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 5.82.
Is LNSR a good stock to buy?
This page provides a data-driven analysis of LENSAR, Inc. (LNSR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.